Outcomes of patients with diffuse systemic sclerosis eligible for autologous stem cell transplantation managed with conventional therapy

ConclusionsASCS patients meeting ASTIS and/or SCOT inclusion criteria who were managed without ASCT have similar event-free survival (EFS) at four years than patients receiving ASCT, and better EFS than those receiving cyclophosphamide in the ASTIS and SCOT trials. This may reflect confounders unable to be controlled for, including survivor bias, but may also reflect improved standard of care for dcSSc over time.

Source: Arthritis and Rheumatology - April 1, 2024 Category: Rheumatology Authors: Kate Gregory, Dylan Hansen, Ross Penglase, Diane Apostolopoulos, Gene ‐Siew Ngian, Wendy Stevens, Kathleen Morrisroe, Nava Ferdowsi, Laura Ross, Jennifer Walker, Helen Cooley, Peter Youssef, Kathleen Tymms, Lauren Host, Susanna Proudman, Tags: Full Length Source Type: research